Intra-Cellular Therapies ... (ITCI)
Intra-Cellular Therapies Statistics
Share Statistics
Intra-Cellular Therapies has 106.33M shares outstanding. The number of shares has increased by 9.51% in one year.
| Shares Outstanding | 106.33M |
| Shares Change (YoY) | 9.51% |
| Shares Change (QoQ) | 0.33% |
| Owned by Institutions (%) | 91.2% |
| Shares Floating | 98.88M |
| Failed to Deliver (FTD) Shares | 4.08K |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 1.5M, so 1.41% of the outstanding shares have been sold short.
| Short Interest | 1.5M |
| Short % of Shares Out | 1.41% |
| Short % of Float | 1.51% |
| Short Ratio (days to cover) | 0.41 |
Valuation Ratios
The PE ratio is -115.34 and the forward PE ratio is 686.6. Intra-Cellular Therapies's PEG ratio is 2.28.
| PE Ratio | -115.34 |
| Forward PE | 686.6 |
| PS Ratio | 12.65 |
| Forward PS | 4.2 |
| PB Ratio | 7.5 |
| P/FCF Ratio | -117.19 |
| PEG Ratio | 2.28 |
Enterprise Valuation
Intra-Cellular Therapies Inc. has an Enterprise Value (EV) of 6.88B.
| EV / Earnings | -92.18 |
| EV / Sales | 10.11 |
| EV / EBITDA | -58.98 |
| EV / EBIT | -58.98 |
| EV / FCF | -93.66 |
Financial Position
The company has a current ratio of 6.36, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.36 |
| Quick Ratio | 6.23 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.46 |
| Cash Flow / Debt | -4.31 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.07% and return on capital (ROIC) is -10.08%.
| Return on Equity (ROE) | -0.07% |
| Return on Assets (ROA) | -0.05% |
| Return on Capital (ROIC) | -10.08% |
| Revenue Per Employee | $791,688.37 |
| Profits Per Employee | $-86,832.56 |
| Employee Count | 860 |
| Asset Turnover | 0.5 |
| Inventory Turnover | 2.17 |
Taxes
| Income Tax | 473K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by 93.76% in the last 52 weeks. The beta is 0.7, so Intra-Cellular Therapies's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | 93.76% |
| 50-Day Moving Average | 128.06 |
| 200-Day Moving Average | 90.45 |
| Relative Strength Index (RSI) | 85.25 |
| Average Volume (20 Days) | 3.21M |
Income Statement
In the last 12 months, Intra-Cellular Therapies had revenue of 680.85M and earned -74.68M in profits. Earnings per share was -0.72.
| Revenue | 680.85M |
| Gross Profit | 623.89M |
| Operating Income | -116.72M |
| Net Income | -74.68M |
| EBITDA | -116.72M |
| EBIT | -116.72M |
| Earnings Per Share (EPS) | -0.72 |
Balance Sheet
The company has 306.95M in cash and 16.98M in debt, giving a net cash position of 289.97M.
| Cash & Cash Equivalents | 306.95M |
| Total Debt | 16.98M |
| Net Cash | 289.97M |
| Retained Earnings | -1.69B |
| Total Assets | 1.37B |
| Working Capital | 1.1B |
Cash Flow
In the last 12 months, operating cash flow was -73.18M and capital expenditures -322K, giving a free cash flow of -73.5M.
| Operating Cash Flow | -73.18M |
| Capital Expenditures | -322K |
| Free Cash Flow | -73.5M |
| FCF Per Share | -0.71 |
Margins
Gross margin is 91.63%, with operating and profit margins of -17.14% and -10.97%.
| Gross Margin | 91.63% |
| Operating Margin | -17.14% |
| Pretax Margin | -10.9% |
| Profit Margin | -10.97% |
| EBITDA Margin | -17.14% |
| EBIT Margin | -17.14% |
| FCF Margin | -10.8% |
Dividends & Yields
ITCI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.55% |
| FCF Yield | -0.52% |
Analyst Forecast
The average price target for ITCI is $99, which is -24.8% lower than the current price. The consensus rating is "Hold".
| Price Target | $99 |
| Price Target Difference | -24.8% |
| Analyst Consensus | Hold |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 37.9 |
| Piotroski F-Score | 2 |